The Qnexa data released Wednesday were impressive, especially from an efficacy standpoint, where weight loss exceeded anything seen to date by competing drugs from Arena Pharmaceuticals ( ARNA) and Orexigen Therapeutics ( OREX). Qnexa will continue to be nagged by worries about safety, primarily the central nervous system side effects of topiramate. Next up is the second phase III weight-loss study from Arena's drug lorcaserin, which should be released before the end of the month. After that, all three weight-loss drugs, Qnexa, lorcaserin and Orexigen's Contrave, will face the scrutiny of obesity doctors at the Obesity Society annual scientific meeting Oct. 24-28. Next up, a compliment from Brad L. He writes, "Hey, I just wanted to say thank you for your great work. I'm an individual investor (my investment income is my livelihood) and I just wanted to say I find your articles to be very valuable. Biotech is such a hard thing to invest in because so few people really understand the underlying science (including me) so it is really good to read from someone who clearly gets it. There is so much hype about biotech stocks (I think because of their size and obscurity) that, truthfully, the articles of yours I find most valuable are the ones where you shoot companies down like Antigenics ( AGEN). Thanks a lot for providing a professional viewpoint. I wanted you to know that there are a lot of real investors out here who really appreciate it." Fan mail is just as fun to receive as hate mail. Thanks for the kind words, Brad, and thanks for being a reader of mine.